Annual Report 2018
Department of Pharmacy
Toshikatsu Kawasaki, Takahiro Nishimura, Mitsue Hirano, Reiko Matsui, Norio Goto, Hisanaga Nomura, Daisuke Kano, Naoko Kumazawa, Shinya Suzuki, Nobuo Mochizuki, Youko Ishikawa, Tomoko Morita, Toshiko Ishihara, Kenji Kawasumi, Ayumi Komuro, Yoshihiro Iwamoto, Takahiro Ohta, Akira Shinohara, Sayaka Nakajima, Misaki Takeno, Nobue Sato, Takayuki Sano, Daisuke Hisamatsu, Masaki Tanaka, Kanako Mamishin, Takashi Igarashi, Tsuyoshi Uemoto, Hayato Kamata, Hirotaka Kikuchi, Takeru Suenaga, Youko Seto, Ken Demachi, Asumi Kaneko
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patientcentered pharmaceutical care.
Our residents' training program started in 2006. In 2018, six residents joined our department. Presently, we have a total of 19 residents. In addition, our department has accepted three trainees from other institutions for our oncology pharmacist training programs in 2018. Through 2018, we trained five pharmacy students and one advanced-training pharmacy student.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, preparing i.v. solutions for chemotherapy, which include the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient's chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. In inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. In outpatient care, our department provides a pharmacy outpatient service in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, especially in the case of oral anticancer medications. We then assess the necessity of supportive-care medications and suggest them to physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to evaluate when patients have to stop their anticoagulants before their operation or when they have to stop to take metformin before examinations with iodinatedcontrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also manage investigational drugs.
Table 1. Pharmacy Achievement
New developments
1) Our department has distributed one pharmacist as a duty pharmacist in the antimicrobial stewardship team (AST) to receive an antibacterial agent adequate use support medical care fee since April 2018.
2) Our department also has distributed two pharmacists as a cancer genome medicine coordinator (CGMC) with the National Cancer Center Hospital East authorized as the designated core hospital for genome medicine.
3) To optimize clinical services, the department has started protocol-based pharmacotherapy management services, which (1) revise minor errors in doctor's prescriptions and (2) order TDM for antibacterial drug use.
List of papers published in 2018
Journal
1. Demachi K, Suzuki S, Kamata H, Suzuki H, Sugama Y, Ikegawa K, Igarashi T, Yamaguchi M. Evaluation of clinical pharmacy service collaborated with oncologists at an outpatient clinic on chemotherapy order prescriptions and adverse drug reaction management in outpatient cancer chemotherapy. European Journal of Oncology Pharmacy, 2:2019
2. Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H, Okano T, Fujisawa T, Ueda Y, Okano S, Tahara M, Yamaguchi M. Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. Front Oncol, 8:616, 2018
3. Shinohara A, Andoh T, Saiki I, Kuraishi Y. Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice. Eur J Pharmacol, 833:275-282, 2018
4. Suzuki H, Suzuki S, Kamata H, Sugama Y, Demachi K, Ikegawa K, Igarashi T, Yamaguchi M. Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J Oncol Pharm Pract, 1078155218798138, 2018